Compare Grab Holdings Ltd. (GRAB) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Grab Holdings Ltd. vs TG Therapeutics Inc — how do they compare? Grab Holdings Ltd. trades at $3.61 (market cap $15.26B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Grab Holdings Ltd. is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Grab Holdings Ltd. nearer its low. Which is the better fit depends on your goals.
| GRAB | TGTX | |
|---|---|---|
Market Cap | $15.26B | $7.64B |
Sector | Technology | Health |
52-Week High | $6.45 | $59.06 |
52-Week Low | $3.27 | $26.94 |
Enterprise Value | $10.99B | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GRAB trades at $3.605, down 1.77% today, but maintains a bullish technical trend. The company reported strong Q2 2026 earnings, beating estimates with $0.06 EPS, and raised full-year revenue guidance to 22-23% growth. Positive analyst sentiment includes an average price target of $5.86, implying 58% upside. Fundamentals show improving profitability, with net income turning positive in 2025 at $268 million and margins expanding.
Outlook is positive given earnings momentum and raised guidance, but risks include high valuation multiples, insider selling, and competitive pressures in Southeast Asia. The stock offers growth potential if execution continues, yet investors should weigh valuation against profitability sustainability and market volatility.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Grab Holdings Ltd.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
